腹膜透析(PD)是肾衰竭患者的重要治疗方式,有利于去除多余的液体和不需要的物质。然而,腹膜炎,PD患者经历的重大并发症,需要仔细选择抗生素以确保成功治疗。PD患者常用的抗生素,如头孢菌素和糖肽,如万古霉素,与不良副作用和高故障率有关。为了应对这些挑战,替考拉宁,一种新型的糖肽抗生素,由于其与万古霉素相似的活性范围而受到关注,延长半衰期,减少副作用,改善消除。本研究的目的是全面回顾疗效,作用机制,不利影响,替考拉宁在腹膜透析患者中的药理作用。我们的研究涉及对来自知名数据库的21篇文章的广泛回顾,包括谷歌学者,PubMed,和科学直接。从这些研究中提取的数据经过精心评估,以全面了解替考拉宁在该特定患者人群中的临床情况。这些研究的主要发现是基于糖肽的方案比第一代头孢菌素或氟喹诺酮类药物有更高的治愈率,和替考拉宁显示出优于万古霉素的几个优点,例如更高的治疗指数,良好的耐受性,更长的半衰期,较低的肾毒性率,改善消除,同时同样有效。替考拉宁通常用于腹膜透析患者,负荷剂量为400毫克,旨在达到10-15毫克/分升的谷浓度。替考拉宁提高了耐受性,缺乏定期的血清水平监测要求,使其成为临床使用的传统抗生素的有希望的替代品。
Peritoneal dialysis (PD) is a vital treatment modality for renal failure patients, facilitating the removal of excess fluid and unwanted substances. However, peritonitis, a significant complication experienced by PD patients, necessitates careful selection of antibiotics to ensure successful treatment. Commonly used antibiotics in PD patients, such as cephalosporins and glycopeptides like vancomycin, have been associated with undesirable side effects and high failure rates. In response to these challenges,
teicoplanin, a novel glycopeptide antibiotic, has gained attention due to its similar range of activity to vancomycin, extended half-life, reduced side effects, and improved elimination. The objective of this study is to comprehensively review the efficacy, mechanism of action, adverse effects, and pharmacological benefits of
teicoplanin in peritoneal dialysis patients. Our research involved an extensive review of 21 articles from reputable databases, including Google Scholar, PubMed, and ScienceDirect. The data extracted from these studies was meticulously evaluated to comprehensively understand
teicoplanin\'s clinical profile in this specific patient population. Major findings of these studies are that glycopeptide-based regimens have higher cure rates over first-generation cephalosporins or fluoroquinolones, and teicoplanin demonstrated several advantages over vancomycin, such as a higher therapeutic index, good tolerance, longer half-life, lower rates of nephrotoxicity, improved elimination while being equally effective.
Teicoplanin is typically administered to peritoneal dialysis patients with a loading dose of 400 mg, aiming to achieve a trough concentration of 10-15 mg/dl.
Teicoplanin\'s improved tolerability and lack of regular serum level monitoring requirements make it a promising alternative to traditional antibiotics for clinical use.